Off-label use of Baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K/Akt/mTOR pathway via targeting JAK-STAT signaling of CD4+ cell... by Shuang Chen, Caihua Li, Caihua Li, Zeng Tu, Tao Cai, Xinying Zhang, Xinying Zhang, Lei Wang, Ruoyuan Tian, Ruoyuan Tian, Jinglan Huang, Jinglan Huang, Yuxuan Gong, Xiaotong Yang, Zetong Wu, Sirong He, Sirong He, Wenyan He, Dan Wang

Connect to this object online.